

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Robert SEEMAYER, et al.

Serial No.: 10/679,961 Group No. 1625

Filed: October 6, 2003 Examiner: P. Morris

For: PROCESS FOR THE PREPARATION OF (S,S)-CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE

Attorney Docket No.: U 014840-0

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450RECEIVED
OCT 27 2004
OFFICE OF PETITIONSINFORMATION DISCLOSURE STATEMENT

We draw the attention of the Examiner to the attached English-language version of an Action or International-type Search Report from a foreign office in respect of counterpart International Application No. US03/32275 that indicates the degree of relevance found by the foreign office. The Search Report makes consideration of any non-English art required. MPEP 609.

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

with sufficient postage as first class mail.

37 C.F.R. 1.10*

as "Express Mail Post Office to Addressee"
Mailing Label No. _____ (mandatory)

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office. to (703) 872-9306

SignatureDate: October 20, 2004

John Richards
(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Form PTO-1449 is also attached with reference copies despite prior citation of the U.S. patent.

Respectfully submitted,

John Richards
c/o Ladas & Parry LLP
26 West 61st Street
New York, New York 10023
Reg. No. 31053
Tel. No. (212) 708-1915

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/32275

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 453/02
US CL : 546/133, 137

RECEIVED

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

OCT 27 2004

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 546/133, 137

OFFICE OF PETITIONS

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN STRUCTURE SEARCH, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SEWARD, E.M. et al.: Quinuclidine-based NK-1 antagonists I: 3-benzyloxy-1-azabicyclo[2.2.2]octanes. Bioorg. & Medicin. Chem. Lett. 1993, Vol. 3, No. 6, pages 1361-1366, especially compounds 16 and 17 on page 1363.	31-34
A	US 5,162,339 A (LOWE, J.A.) 10 November 1992 (10.11.1992), column 14, lines 45-57.	1-30

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 17 February 2004 (17.02.2004)	Date of mailing of the international search report 17 MAR 2004
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer Valerie Bell-Hansen Alan Rotman Telephone No. (703)308-1235

Form PCT/ISA/210 (second sheet) (July 1998)

FORM PTO-1449		U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.	SERIAL NO.
				U 014840-0	10/679,961
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT	
		(Use several sheets if necessary)		Robert SEEMAYER, et al.	
				FILING DATE	GROUP
				October 6, 2003	1625

U.S. PATENT DOCUMENTS					
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA	5,162,339	10/1992	LOWE, III	
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK.				

RECEIVED
OCT 27 2004
OFFICE OF PETITIONS

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES
	AL				
	AM				
	AN				
	AO				
	AP				

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)		
	AR	Seward, E. M., "Quinuclidine-Based NK-1 Antagonists I: 3-Benzylxy-1-Azabicyclo[2.2.2]Octanes", <i>Bioorganic & Medical Chemistry Letters</i> , Vol. 3, No. 6, pp. 1361-1366, 1993
	AS	
	AT	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	